Insmed (INSM) Set to Announce Earnings on Thursday

Insmed (NASDAQ:INSM) is scheduled to release its earnings data before the market opens on Thursday, August 8th. Analysts expect Insmed to post earnings of ($1.22) per share for the quarter. Insmed has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.16. The business had revenue of $75.50 million for the quarter, compared to the consensus estimate of $77.76 million. The company’s revenue was up 15.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.17) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $72.68 on Wednesday. The firm has a market cap of $10.80 billion, a PE ratio of -13.90 and a beta of 1.16. Insmed has a 52 week low of $21.21 and a 52 week high of $78.87. The firm’s fifty day moving average is $67.80 and its 200-day moving average is $41.41.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 22,198 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $25.52, for a total value of $566,492.96. Following the transaction, the chief executive officer now directly owns 384,125 shares of the company’s stock, valued at approximately $9,802,870. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Insmed news, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total transaction of $1,165,725.00. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at $5,837,370. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 22,198 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $25.52, for a total transaction of $566,492.96. Following the sale, the chief executive officer now owns 384,125 shares in the company, valued at $9,802,870. The disclosure for this sale can be found here. Insiders sold 295,842 shares of company stock worth $13,762,062 in the last quarter. 4.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of recent analyst reports. Mizuho lifted their price objective on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Guggenheim increased their price objective on shares of Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. The Goldman Sachs Group boosted their target price on shares of Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Truist Financial increased their price target on Insmed from $68.00 to $88.00 and gave the stock a “buy” rating in a report on Monday, July 1st. Finally, Wells Fargo & Company boosted their price objective on Insmed from $55.00 to $77.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus target price of $74.50.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.